XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:              
Net loss $ (25,165,478) $ (30,469,871) $ (33,929,864) $ (40,649,317) $ (87,872,447) $ (110,113,714)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,335,326 2,051,962  
Amortization of intangible assets         0 145,417  
Amortization of operating lease right-of-use assets         1,018,887 1,130,932  
Impairment of goodwill 0   10,513,371   0 10,513,371  
Impairment of intangible assets         0 1,984,444  
Non-cash stock-based compensation         5,279,344 8,806,188  
Non-cash interest on senior convertible notes         (355,654) (126,511)  
Amortization of discounts on investments         (1,510,276) (3,641,765)  
Loss on sales of short-term investments         1,278,959 3,853,691  
Loss on disposal of fixed assets         21,930 364,422  
Loss (gain) on equity investment in affiliated entity (324,251)   (214,374)   136,061 (987,758)  
Net unrealized gain on available-for-sale equity securities (1,330,811)   219,337   (1,810,868) (3,921,819)  
Changes in operating assets and liabilities:              
Accounts receivable from affiliated entities         542,489 9,594,021  
Prepaid expenses and other current assets, including from affiliated entities         796,981 39,285,174  
Other assets         38,900 78,729  
Accounts payable and accrued expenses, including due to affiliated entities         (4,340,806) (50,641,862)  
Accrued clinical trial expenses         2,131,186 (5,582,888)  
Operating lease right-of-use assets and liabilities, net         (993,249) (2,147,175)  
Grant funding liability, including from affiliated entity         (109,407) 1,265,375  
Net cash used in operating activities         (84,412,644) (98,089,766)  
Cash flows from investing activities:              
Purchases of investments         (54,138,027) (174,250,213)  
Proceeds from sale or maturity of investments         124,052,574 235,912,707  
Purchases of capital assets         (487,832) (320,898)  
Proceeds from sale of capital assets         0 6,071,000  
Net cash provided by investing activities         69,426,715 67,412,596  
Cash flows from financing activities:              
Repayment of convertible senior notes         (16,415,000) 0  
Proceeds from issuance of pre-funded warrants, net of issuance costs         16,146,397 0  
Proceeds from issuance of common stock, net of issuance costs         22,951,867 3,623,462  
Proceeds from stock option exercises         67,675 0  
Taxes paid related to net share settlement of equity awards         (420,795) (466,646)  
Net cash provided by financing activities         22,330,144 3,156,816  
Effect of exchange rate changes on cash and cash equivalents         32,403 (4,403)  
Increase in cash and cash equivalents         7,376,618 (27,524,757)  
Cash and cash equivalents, beginning of period   $ 14,310,862   $ 46,329,359 14,310,862 46,329,359 $ 46,329,359
Cash and cash equivalents, end of period $ 21,687,480   $ 18,804,602   21,687,480 18,804,602 $ 14,310,862
Supplemental disclosures:              
Interest paid         533,487 1,066,975  
Issuance of common stock as part of litigation settlement         $ 0 $ 14,000,000